Psyence Biomedical Ltd. (PBM), through its wholly owned subsidiary Psyence Biomed II Corp., completed an additional US$2,599,896 investment in PsyLabs after both milestones tied to its backstop commitment were achieved. The subsidiary subscribed for 1,014 PsyLabs ordinary shares at US$2,564 per share, at the financing round’s US$54 million pre-money equity valuation. PBM held approximately 41.13% of PsyLabs’ issued and outstanding shares immediately before the investment; following completion and giving effect to a share exchange that closed October 1, 2026, it held approximately 43.37%. The investment was funded from PBM’s existing cash resources.
The milestones were completion of an ibogaine regulatory-readiness documentation package and a manufacturing services agreement between PBM subsidiary Texas Ibogaine Research Corporation and Benuvia, which operates a controlled-substance facility in Round Rock, Texas, registered with the U.S. Drug Enforcement Administration. The agreement is intended to support planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient under cGMP standards, subject to applicable regulatory requirements. PsyLabs is expected to be TIRC’s exclusive U.S. ibogaine supplier under a binding term sheet, subject to a definitive agreement the parties agreed to conclude on or before November 30, 2026. No clinical trial has commenced, and no regulatory application in respect of it has been filed or accepted.
Psyence Biomedical Ltd. issued 1,497,500 common shares to Psyence Labs Ltd. on October 1, 2026, at a deemed issue price of US$6.00 per share under a share-for-share swap. In exchange, Psyence Labs issued 3,473 of its ordinary shares to Psyence Biomed II Corp., the issuer’s wholly owned subsidiary, at the issuer’s direction. The exchange was described as equal in agreed value, with aggregate non-cash consideration of US$8,985,000; no party paid cash.
After the issuance, Psyence Labs beneficially owned 2,643,659 PBM common shares, approximately 49.75% of the 5,314,048 shares outstanding immediately afterward on October 1, 2026. It may be deemed an affiliate and control person. While Psyence Labs and its affiliates own any issuer shares, the agreement restricts specified acquisitions, proxy activity, governance actions and transactions; certain actions require stated consents or approvals. The additional shares also cannot be transferred without an effective registration statement or an available exemption.
PSYENCE BIOMEDICAL LTD. (PBM) is the issuer whose common shares AdvisorShares Trust reported beneficially owning. As of September 30, 2026, the reporting person held 258,538 shares, or 6.78% of the class. It reported sole voting and dispositive power over 258,538 shares and no shared voting or dispositive power.
Psyence Biomedical Ltd. said its wholly owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), entered a manufacturing services agreement with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient under current Good Manufacturing Practice (cGMP) standards. Benuvia operates a DEA-registered facility of approximately 83,000 square feet in Round Rock, Texas. According to Benuvia, it holds approximately half of the U.S. aggregate production quota for ibogaine; Psyence said information about Benuvia, including its facility and quota, was provided by Benuvia and has not been independently verified.
The partnership builds on TIRC’s binding term sheet with PsyLabs, a significant Psyence shareholder in which Psyence holds an ownership interest, for an exclusive U.S. license, supply and wholesale distribution arrangement. The parties agreed to conclude a definitive agreement on or before November 30, 2026. Benuvia is advancing applications for the import permit and procurement quota required for planned production. Psyence says production timing and scale will be governed primarily by DEA quotas, controlled-substance import requirements and other authorizations. Ibogaine has not been approved for therapeutic use, and its safety and efficacy have not been established through authorized clinical research.
Psyence Biomedical Ltd.’s wholly owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), entered a binding term sheet with Psyence Labs Ltd. (PsyLabs) on September 25, 2026. It provides for PsyLabs to grant TIRC exclusive U.S. rights to use PsyLabs’ ibogaine hydrochloride know-how and technical materials to develop, manufacture and commercialize drug candidates. PsyLabs will exclusively supply TIRC; TIRC will be PsyLabs’ exclusive U.S. wholesaler and distributor, while PsyLabs retains rights elsewhere.
TIRC will pay up to approximately US$1.3 million in development and regulatory milestones for the first drug candidate, plus an annual exclusivity fee beginning on the first anniversary of the first FDA approval and creditable against royalties, a low single-digit percentage royalty on each candidate’s net sales, and margin-sharing on TIRC product resales. Exclusivity depends on TIRC sourcing all U.S. ibogaine requirements from PsyLabs, subject to customary supply-failure step-in rights; minimum development and/or sales thresholds are expected in the definitive agreement. That agreement is due by November 30, 2026, or the term sheet lapses; until it takes effect, the term sheet governs its covered matters. PsyLabs is a significant shareholder, Psyence Biomedical holds an ownership interest in PsyLabs, and certain Company management members are PsyLabs affiliates with financial interests, making this a related-party transaction.
PSYENCE BIOMEDICAL LTD. (symbol: PBM) is the issuer of record for a Form 6-K filing submitted to the SEC.
Psyence Biomedical Ltd. (PBM) announced the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary created to coordinate its U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to be the dedicated U.S. vehicle for regulated ibogaine development.
Subject to definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, in which Psyence BioMed holds an ownership interest, and will be financed by Psyence BioMed. Jody Aufrichtig will serve as Chief Executive Officer of both Psyence BioMed and TIRC, with Dr. John Thorne as project lead. The company highlights that ibogaine remains a controlled substance and is not approved for therapeutic use, and it outlines regulatory, financing and policy risks that could affect the planned activities.
Psyence Biomedical Ltd. presents an August 2026 investor update describing its clinical-stage focus on nature-derived psychedelic therapeutics for mental health in cancer palliative care, Alcohol Use Disorder, Substance Use Disorder and longevity science. The company highlights having no debt, a strong cash position and two low-cost financing mechanisms, and a vertically integrated platform via a strategic equity stake and supply partnership with PsyLabs for GMP-compliant psilocybin, ibogaine, DMT and mescaline.
The presentation details an Australian Phase IIb trial of NPX-5, a botanical psilocybin, for Adjustment Disorder associated with cancer in the palliative care setting, with 87 patients across three dose arms and a HAM-A primary endpoint at ten weeks, following HREC ethics approval, first patient dosing and FDA Pre-IND feedback. Psyence BioMed outlines an anticipated pathway with topline results planned in H1 2027 and future regulatory interactions, and emphasizes intellectual property efforts and potential data exclusivity. It also describes its ibogaine program, notes a $23.3B projected global palliative care market by 2032 and references a recent U.S. executive order committing $50 million to ibogaine research, framing a supportive external environment for its pipeline.
Psyence Biomedical Ltd. files its annual Form 20-F as a clinical-stage biotechnology company focused on psilocybin-based therapies. The report emphasizes that the company has never generated revenue and recorded net profit/(loss) of ($6.89 million), $1 million and ($50.96 million) for the years ended March 31, 2026, 2025 and 2024, respectively.
Psyence discloses it is financing operations through equity and convertible debt, expects significant losses for the foreseeable future, and will require substantial additional funding to advance its Phase IIb study in Australia and potential Phase III program. As of March 31, 2026, cash, cash equivalents and restricted cash totaled USD$7,491,954, which management expects will fund operations beyond 12 months from the filing date.
The company outlines extensive risks, including clinical, regulatory and supply-chain uncertainty, dependence on key partners and licensed IP, U.S. Schedule I status for psilocybin and ibogaine, intense competition in psychedelic therapies, evolving governmental policy, and the possibility that future research, regulation or public perception could materially harm demand for its prospective products.
PSYENCE BIOMEDICAL LTD. amendment reports that Jeffrey David Weiner beneficially owns 59,750 common shares, equal to 2.61% of the class. The filing states this percentage is based on 2,293,307 total outstanding shares reported by the company. The form is signed on 06/09/2026 and is labeled as an amendment to prior ownership disclosure.